cyrilzakka/clinical-trials huggingface dataset:
Post Traumatic Stress Disorder and Neural Mechanisms Involved in Its Treatment

The post traumatic stress disorder PTSD arises when the physiological response to stress does not come to its term. This study aims to explore the cognitive, psycho physiological and cerebral mechanisms involved in PTSD, in fear conditioning and face matching tasks, before and after treatment.PTSD patients will be recruited by Pr Jean-Claude Samuelian in his service at the Conception Hospital and by Pr Jean-Michel Azorin in his service at the Sainte Marguerite Hospital (Marseille) and will undergo either CBT or EMDR within those same services. The tasks they will be asked to perform will study the psycho physiological, cognitive and central mechanisms involved in PTSD and its treatment. All in all, 17 healthy controls will be recruited as well as 17 PTSD patients for each of the two treatment group.In terms of perspectives, this study would help isolate neural systems functionally involved in PTSD and its treatment. A better knowledge of those mechanisms would set room for the optimization of the current PTSD treatment.


Eligibility Criteria:
Inclusion Criteria:

* French speakers
* Not hospitalized grown-up patients suffering from a post-traumatic stress disorder ( PTSD) connected to one event.
* Subjects Controls: grown-up, mated with the patients in age (18 - 50 years; 4 years maximum of difference of age between a patient and his control), in sex and educational level (schooling of the 3rd level, at the level Bac+8; 3 years maximum of difference of educational level between a patient and his control)

Exclusion Criteria:

* Pregnancy
* Feeding
* Nobody under guardianship and grown-up persons being the object of a legal protective measure or not able to express their assent
* Alcoholic or addicted to drugs (including medicines)
* Other neurological disorders or psychiatric that post-traumatic stress disorder (for patients)
* Claustrophobia and contraindications in the IRMf
* Subjects controls, no known psychiatric or neurological pathology, as well as no psychiatric history.
* Persons private of freedom by a court or administrative order, persons hospitalized without assent
* Unability to read French
Glottic Opening Percentage (POGO) With Miller and McGrath MAC Videoingoscopes

The aim of this study is to compare the percentage of glottic opening (POGO) with Miller and McGrath MAC Videoingoscopes compared to the direct epiglottis lifting method.

The aim of this study is to compare the percentage of glottic opening (POGO) with Miller and McGrath MAC Videoingoscopes compared to the direct epiglottis lifting method.

Eligibility Criteria:
Inclusion Criteria:

* Those who agreed to participate in the study
* He will undergo elective surgery
* Endotracheal intubation required
* 18-65 years old
* ASA 1-2 risk
* Body mass index\<30
* No risk of difficult intubation

Exclusion Criteria:

* Those who do not want to participate in the study,
* Allergic to study drugs,
* Pregnant women
* Those with a history of difficult intubation
* They will be applied rapid-serial intubation
* Emergency
Assessment of the Sexuality of the Infertile Couple

The study hypothesis is that infertile couples experience an impact of their sexuality impacted during the diagnostic process carried out as part of the medically assisted procreation assessment, and also by the announcement of the possible cause of the couple's infertility. It is also conceivable that a disorder of the couple's sexuality forms the origin of, or is a contributor to, infertility.


Eligibility Criteria:
Inclusion Criteria:

* Couple in which each of the two partners has signed the consent form which is presented separately and independently of their partner.
* The patient must be a member or beneficiary of a health insurance plan
* Heterosexual infertile couple (according to the WHO definition) monitored at the Nîmes University Hospital in the urology / gynecology departments.

Adult patient (≥18 years old) and under 43 years old for women, 60 years old for men

Exclusion Criteria:

* The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
* One member of the couple refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Patient without good level of written and spoken French
Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose

The purpose of this study is to determine which route of administration is better for treatment of opioid overdosed patients

In intravenous drug abusers (IDUs), as a result of previous intravenous substance abuse, the predictable difficult cannulate exist and cause the delay administration of antidote therapy. Additionally, IDUs are also at increased risk of carrying blood borne infections that could be transmitted to healthcare workers through needle stick injuries. The investigators aimed to compare intranasal administration of naloxone with intravenous route.

Eligibility Criteria:
Inclusion Criteria:

* Patients with the range of 15-50 years old

  * Who were suspicious to opioid overdoses based on history and having clinical appearance such as miotic pupils with loss of consciousness
  * Give response to naloxone with increasing the level of consciousness

Exclusion Criteria:

* Not giving response to naloxone and suspicious to have another reason for loss of consciousness
Myotonia and Muscle Stiffness in NMD

The primary objective of this study is to assess stiffness, muscle tone, relaxation periods and elasticity of various muscles in patients with dystrophic or non-dystrophic myotonia. The secondary objectives are (1) to provide reference values for stiffness, muscle tone, relaxation periods and elasticity of various muscles in patients with dystrophic or non-dystrophic myotonia; to provide reference values for stiffness, muscle tone, relaxation periods and elasticity of various muscles in patients with non-myotonic neuromuscular disorders, (3) assess correlations between to compare result values for stiffness, muscle tone, relaxation periods and elasticity with clinical muscle function tests, measured by clinical evaluation (MRC-scale) and the 6-minute walk test; (4) assess correlations between subcutaneous fat and muscle thickness and echogenicity, measured by muscle ultrasound and result values for stiffness, muscle tone, relaxation periods and elasticity.


Eligibility Criteria:
Inclusion Criteria:

For Patients:

* ≥18 years of age
* Confirmed neuromuscular disease
* written consent
* able and willing to perform study prodcedures

For healthy volunteers:

* age ≥18 years of age
* written informed consent
* no clinical sign for neuromuscular disorders

Exclusion Criteria:

* Severe comorbidities
* Patient is participating in another clinical study using investigational treatment
* Patient cannot perform required muscle function tests
* the patient, in the opinion of the investigator, is unable to adhere to the requirements of the study
Effectiveness of Trained Religious Leaders' Engagement in Maternal Health Education in Ethiopia

Community education and demand generation activities by involving family members, traditional and religious leaders in maternal health behaviours are potential solutions. Knowledge about maternal and neonatal health service utilization can be increased through community-based structures, such as religious organizations.

Religious and faith community health promotions have the ability to reduce health inequities, and religious institutions are among the most respected and trustworthy institutions that can considerably boost public health work. Similarly, Faith leaders, in addition to physicians and health care providers, are another category of people who have a big impact on other people's beliefs, feelings, and behaviors, according to research. Spiritual leaders have the ability to impact health behavior on a variety of levels, from personal to ecological, with "knock-on" implications on community health. This is achieved via health education and health promoting strategies. Furthermore, the influence of faith leaders on health behavior is in line with the tenets of the Ottawa Charter for Health Promotion since they are perceived as strengthening community action. That is, communities must be empowered to participate in and govern their own affairs. A faith leader is in a unique position to encourage behavior change since he or she is a vital component of the community. According to an evaluation of programs involving faith-based organizations, clergy were able to considerably aid behaviour change, particularly among hard-to-reach populations. Other studies have also identified the importance of faith leader's influence on health behavior. Similarly, faith leaders influence on behavior has been attributed to Scripture-based passages that espouse the virtues of healthy living. Although some studies have suggested that spiritual leaders play a role in influencing congregants' health behaviors, little information on the amount of this influence and the mechanisms involved available.

In Ethiopia, the majority of the population belongs to a religious group, and religion is an important part of society. Through places of worship, religious institutions have access to a large portion of the population. Religious leaders serve as community leaders as well as gatekeepers of information and access to the population and can help raise awareness about underutilized maternal and neonatal health services. Therefore this cluster-randomized trial is designed to evaluate the effects of trained religious leaders' engagement in maternal health education in improving maternal health service utilization and knowledge of major obstetric danger signs.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women less than 20 weeks gestational age
* Living in selected kebele (small administrative unit in Ethiopia)
* Pregnant women willing to participate in the study

Exclusion Criteria:

• Pregnant women who are seriously ill and unable to communicate will be excluded from the study.
Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

The objective of the study is to investigate whether ketoconazole affects plasma exposure of BI 113823


Eligibility Criteria:
Inclusion criteria:

healthy male subjects
Risk Factors of Breastfeeding Study

The goal of this study is to identify infants who are at risk for developing problems related to being breast-fed.

The goal of this study is to identify infants who are at risk for developing problems related to being breast-fed. A previous study identified items that place an infant at a high risk for developing complications related to being breast-fed. The present study will use the same survey and collect data from more participants. These additional participants are necessary to provide statistical analysis for the survey. The survey being developed will assist health care professionals to identify those infants at risk for developing health problems related to being breast-fed and provide care that will minimize the chances of developing complications.

Eligibility Criteria:
Inclusion Criteria:

* Mothers of healthy infants that are breastfeeding
* At least 24 hours post delivery
* Mother and baby will be dismissed from the hospital together.

Exclusion Criteria:

* Mothers of newborns that are not breastfeeding
* Mothers of newborns that are ill and/or will not be dismissed from the hospital at the same time as the mother
Sinecort Pilot Efficacy Study

The study shall prove whether treatment of atopic dermatitis is equally effective with Sinecort cream as compared to standard therapy (Hydrocortisone cream).


Eligibility Criteria:
Inclusion Criteria:

* Male or female Caucasians aged between 18 and 65 years
* Patients with mild AD presenting a scoring AD (SCORAD) rating between 3-25
* Skin type I - IV according to Fitzpatrick
* Acute AD symptoms on each assessment areas (local SCORAD \>/=3 and \<= 12)
* Acute symptom of pruritus at Baseline

Exclusion Criteria:

* Any other skin disease at the test area that would interfere the clinical assessment in the opinion of the investigator
* Moles, tattoos, strong pigmentation, or scars at the test area that would interfere the clinical assessment
* Regular intake of antiphlogistic drugs (for example, NSAIDs)
* Any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of AD lesions other than the test areas (for example, face) with low potency steroids restricted to small areas)
* UV-therapy or the use of solarium within 30 days before screening as well as during the trial
* Any alternative treatment of AD (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial
An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes

This study evaluates the antimicrobial properties of HEXI-PREP by Clinell compared to both a negative and a positive control product.

HEXI-PREP by Clinell is a sterile single sachet wipe containing chlorhexidine gluconate and isopropyl alcohol. Both active ingredients are well-established ingredients commonly used for their disinfectant properties.

This trial is designed to assess the superiority of HEXI-PREP by Clinell Wipe against a negative control, and also to demonstrate the relative efficacy of HEXI-PREP by Clinell WIpe against a similar commercially available product.

Eligibility Criteria:
Inclusion Criteria:

* Male and female participants 18 - 70 years, who have provided written informed consent to participate in the study
* Test sites with a bacterial baseline count of ≥ 5.0 log10/cm2 at the inguinal (groin) test administration sites. ≥4.0 log10/cm2 at the abdominal test site and \>3.0 log10/cm2 at the clavicular and/or median cubital regions at Day - 5 of screening
* Participants, who in the opinion of the Investigator, are in suitable health for inclusion in the study.

Exclusion Criteria:

* Exposure of the test sites to strong detergents, solvents or other irritants during the 14- day pre-test conditioning period or during the test period.
* Use of systemic or topical antibiotic medications, steroid medications or any other product known to affect the normal microbial flora of the skin, up to 1 month prior to the screening period, during the 14-day pre-test conditioning period or during the test period.
* Any known allergies to latex (rubber), alcohols, tape adhesives or to common antibacterial agents found in soaps, lotions or ointments, particularly chlorhexidine gluconate or chlorine.
* Active skin rashes or breaks in the skin at the test site.
* Active skin diseases or inflammatory skin conditions including contact dermatitis within 10cm of the test site.
* Showering or bathing after the Day -5 baseline sampling and unwilling to refrain from showering or bathing whilst at Surrey CRC (Day 0 to Day 1).
* Participation in another clinical trial within 90 days preceding randomisation.
* Pregnant or breastfeeding women.
* Any other medical condition, which in the opinion of the Investigator, should preclude participation.
* Unwillingness to fulfil the performance requirements of the study.
Evaluation of The Fear of Childbirth

Most pregnant women have fear of labor. The reasons of fear of labor are different according to women. The investigators will examine the relationship between the descriptive features and level of fear of labor of pregnant women by using the Oxford worries about labour scale

The investigators will give a survey to pregnant women who go to the antenatal polyclinic. The survey is consisted by researchers. The survey has a few questions about pregnant women's descriptive features. Next the investigators will evaluate the level of fear of labor of pregnant women. After the investigators will analyze the relationship between pregnant women's fear and their descriptive features.

Eligibility Criteria:
Inclusion Criteria:

* all of volunteers and pregnant women who are 18-35 years old.

Exclusion Criteria:

* the pregnant women have any obstetrical complications.
EFFECTIVENESS OF THE NEUROADAPTATIVE FOR URGE INCONTINENCE

In this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence

In this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence and mixted incontinence

Eligibility Criteria:
Inclusion Criteria:

* Urge incontinence or mixed incontinence without urethral hypermobility
* Over 3 months of disease evolves.

Exclusion Criteria:

* Severe physical limitations that might interfere with applying the treatment.
* Severe mental disorders that need pharmacology treatments that may influence in neuronal activity
* Oncological processes in the lower abdomen that had required radical surgery.
* Neurogenic bladder.
* Blockage of the bladder
* Vaginal infection
* Bladder infection or disorder of kidney function
* Have received, in the last year, botulinum toxin in bladder or pelvic organs.
* Have received pharmacological treatment for urge incontinence in the last month (before entry date in the trial)
* Be receiving pharmacological treatment for urge incontinence.
* Stress incontinence due to urethral hypermobility which was treatable with surgery.
* Pregnant women
* Patients with pacemarker
Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Study to determine the pharmacokinetic effect of BILR 355 + ritonavir® on TRUVADA and TRUVADA on BILR 355


Eligibility Criteria:
Inclusion Criteria:

* Males and Females who meet the inclusion/exclusion criteria; females must not be pregnant or nursing, and must agree to use a double-barrier method of birth control (condoms or diaphragm, plus spermicide) throughout the trial (alone or in addition to other methods of birth control such as oral contraceptives)
* Age ≥18 and \<60 years
* Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
* Ability to give signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and the local regulations

Exclusion Criteria:

* Current (symptomatic within the last 30 days) and medically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Surgery of gastrointestinal tract (except appendectomy)
* Currently active (symptomatic within the last 30 days) diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* History of relevant orthostatic hypotension, fainting spells or blackouts
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Intake of drugs with a long half-life (\>24 hours) within one month prior to administration of study drug or during the trial (review with clinical monitor if questionable)
* Use of drugs within 10 days prior to administration or during the trial, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation (review with clinical monitor if questionable)
* Participation in another trial with an investigational drug within one month prior to administration or during the trial
* Current smoker
* Alcohol (more than 60 g/day) or drug abuse (positive urine test for illicit prescription or non-prescription drugs or drugs of abuse)
* Recent blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
* Excessive physical activities (within 1 week prior to study drug administration or during the trial)
* Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator
* Inability to comply with dietary regimen required by the protocol
* Chronic or relevant acute infections
* Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B surface antigen, or hepatitis C antibody positive)
* HIV-1 infected as defined by a positive HIV ELISA test
A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin.


Eligibility Criteria:
Inclusion criteria:

* Signed written informed consent
* Male and female patients \> or = 18 years of age with a solid tumor(s) that is locally advanced or metastatic for which single agent carboplatin, or docetaxel or capecitabine would be appropriate
* Measurable disease
* Immunohistochemical evidence of N-cadherin expression in tumor tissue
* Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ECG

Exclusion criteria:

* Receipt of ADH-1 prior to this clinical study
* Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry
* History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months
* History of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry
* Stroke, major surgery, or other major tissue injury within 4 weeks before study entry
* Uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states